(Registration Number: 200717793E)



UNAUDITED FINANCIAL STATEMENT ANNOUNCEMENT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2020

1 (a) (i) Income statement (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

	2020	2019	Change
	US\$'000	US\$'000	%
Revenue	104,284	104,065	0.2%
Cost of sales	(76,103)	(81,720)	-6.9%
Gross profit	28,181	22,345	26.1%
Fair value changes of biological assets and other			
receivables, net	8,885	8,776	1.2%
Distribution costs	(1,807)	(2,569)	-29.7%
Administrative expenses	(8,521)	(8,692)	-2.0%
Other losses, net	(286)	(3,912)	-92.7%
Operating profit	26,452	15,948	65.9%
Gain/(Loss) on foreign exchange	(2,729)	7,570	n/m
Interest income	872	3,348	-74.0%
Interest expense	(16,893)	(20,470)	-17.5%
Share of results from equity-accounted joint	(149)	(4,992)	-97.0%
Profit before income tax	7,553	1,404	438.0%
Income tax expense	(3,532)	(11,790)	-70.0%
Profit/(Loss) from continuing operation	4,021	(10,386)	n/m
Loss from discontinued operation		(2,435)	n/m
Net profit/(loss) for the year	4,021	(12,821)	n/m

n/m: not meaningful

(Registration Number: 200717793E)



1 (a) (ii) Net profit/(loss) is arrived at after charging/(crediting) the following significant items:

	2020	2019	Change
<u> </u>	US\$'000	US\$'000	%
	46.400	17.050	5 0/
Depreciation and amortisation expenses	16,138	17,050	-5%
Loss/(Gain) on foreign exchange	2,729	(7,570)	n/m
Interest expense	16,893	20,470	-17%
Interest income	(872)	(3,348)	-74%
Fair value changes of biological assets	(8,437)	(9,253)	-9%
Fair value changes of other receivables (plasma)	(448)	477	n/m
Loss/ (Gain) on disposal of property, plant and equipment	-	66	n/m
Loss/ (Gain) on disposal of bearer plants	105	11	855%
Impairment on property, plant and equipment	-	474	n/m
Plasma management fee	587	(871)	n/m
Impairment of other receivables (joint venture)	195	4,120	-95%
Sale of waste	(156)	(789)	-81%
Withholding and other tax expenses	856	904	-5%
Additional information :			
EBITDA (excluding fair value changes of biological assets)	31,275	23,888	31%

n/m : not meaningful

(Registration Number: 200717793E)



1 (a) (iii) Statement of comprehensive income (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

	2020	2019	Change
	US\$'000	US\$'000	%
Net profit/(loss) for the year	4,021	(12,821)	n/m
Other comprehensive (loss)/income Items that may be reclassified subsequently to profit or loss: Exchange differences on translating IDR functional currency to US\$ presentation currency, net of tax	42	422	-90%
Items that will not be reclassified subsequently to profit or loss: Actuarial gain/(loss) on post-employment benefits Total comprehensive profit/(loss) for the year	(228)	111 (12,288)	n/m n/m
Profit/(Loss) attributable to owners of the parent, net of tax	4,021	(12,821)	n/m
Profit /(Loss) attributable to non-controlling interests, net of tax	-	-	n/m
Profit/(Loss) for the year, net of tax	4,021	(12,821)	n/m
Total comprehensive profit/(loss) attributable to owners of the parent Total comprehensive profit/(loss) attributable to non-controlling interests Total comprehensive profit/(loss) for the year	3,835	(12,288)	n/m
	-	-	n/m
	3,835	(12,288)	n/m

n/m : not meaningful

(Registration Number: 200717793E)



1 (b) (i) Statement of financial position (for the issuer and group) together with a comparative statement as at the end of the immediately preceding financial year.

	Gro	oup	Company	
	As at 31/12/20	As at 31/12/19	As at 31/12/20	As at 31/12/19
	US\$'000	US\$'000	US\$'000	US\$'000
ASSETS				
Current assets:				
Cash and cash equivalents	13,859	22,349	71	33
Trade and other receivables	35,536	35,947	32,553	36,880
Inventories	10,735	12,135	52,555	50,000
Biological assets	23,841	15,315	_	_
Other assets	1,904	1,174	1	1
Financial assets	-	-	1	1
			-	-
Assets held for sale	4,864	6,431	- 22 625	20.014
Total current assets	90,739	93,351	32,625	36,914
Non-current assets:				
Investments in subsidiaries	-	-	37,320	37,868
Other receivables	4,582	6,805	-	-
Property, plant and equipment	70,695	79,850	-	-
Bearer plants	129,303	136,473	-	-
Land use rights	33,179	34,887	-	-
Deferred tax assets	5,448	6,460	-	_
Right-of-use-assets	489	670	-	-
Total non-current assets	243,696	265,145	37,320	37,868
TOTAL ASSETS	334,435	358,496	69,945	74,782
LIABILITIES AND EQUITY				
Current liabilities:				
Tax payables	3,904	3,525	-	_
Trade and other payables	59,557	78,786	82	3,073
Finance leases	252	354	-	-
Other financial liabilities	46,740	65,096	_	-
Total current liabilities	110,453	147,761	82	3,073
Non-current liabilities:				
Deferred tax liabilities	2,345	1,903	_	_
Finance leases	24	272	_	_
Other financial liabilities	201,785	193,359	_	_
Other liabilities	6,137	5,345	_	_
Total non-current liabilities	210,291	200,879		
Capital and reserves:				
Share capital	93,860	93,860	93,860	93,860
Other reserve	2,485	2,485	-	-
(Accumulated losses)/retained earnings	(40,959)	(44,752)	2,629	3,437
Translation reserve	(41,695)	(41,737)	(26,626)	(25,588)
Total equity	13,691	9,856	69,863	71,709
TOTAL LIABILITIES AND EQUITY	334,435	358,496	69,945	74,782

(Registration Number: 200717793E)



1 (b) (ii) Aggregate amount of group's borrowings and debt securities.

	As at 31/12/2020 US\$'000	As at 31/12/2019 US\$'000
Amount due within one year Secured	46,992	65,450
Amount due more than one year Secured	201,809	193,631

The secured borrowings are secured by way of negative pledges on certain deposits, inventories, trade receivables, land use rights, investment property, bearer plants, property, plant and equipment and biological assets of the Group.

(Registration Number: 200717793E)



1 (c) Statement of cash flows (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

. , , , , , , , , , , , , , , , , , , ,	2020	2019
	US\$'000	US\$'000
Cash flows from operating activities		
Profit before income tax from continuing operations	7,553	1,404
Loss before tax from discontinued operations		(2,435)
Profit/(Loss) before tax, total	7,553	(1,031)
Adjustments for:	(070)	(0.040)
Interest income	(872)	(3,348)
Interest expense	16,893 1,259	20,470
Amortisation of land use rights Depreciation expense	14,879	1,353 15,740
Fair value changes in biological assets	(8,437)	(9,253)
Fair value changes in other receivables	(448)	(<i>5,233</i>) 477
Loss on disposal of bearer plants	105	-
Provision for employment pension benefits	641	878
Loss on disposal of property, plant and equipment	1	66
Impairment allowance on property, plant and equipment	-	474
Impairment on other receivables (joint venture)	195	4,120
Share of results from equity-accounted joint ventures from continuing operations	149	4,992
Share of results from equity-accounted joint ventures from discontinued operations	-	2,435
Bearer plants written off	-	218
Net effect of exchange rate changes in consolidating entities	3,187	(6,766)
Operating cash flows before changes in working capital	35,105	30,825
Inventories	1,224	1,382
Trade and other receivables	5,118	(1,498)
Other assets	(576)	1,032
Trade and other payables	(20,180)	15,676
Net cash flows from operations before tax	20,691	47,417
Income taxes paid	(678)	(2,900)
Net cash flows from operating activities	20,013	44,517
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,316)	(3,618)
Disposal of property, plant and equipment	57	142
Additions to bearer plants	(628)	(1,200)
Purchase of land use rights	(98)	(63)
Interest received	543	849
Refundable deposit received in respect of discontinued operations	-	1,500
Net cash flows used in investing activities	(1,442)	(2,390)
Cash flows from financing activities		_
Cash restricted in use	-	(576)
Proceeds from borrowings	99,082	299,547
Repayment of borrowings	(107,658)	(315,287)
Finance lease repayments	(339)	(134)
Interest paid	(17,830)	(21,815)
Net cash flows used in financing activities	(26,745)	(38,265)
Net decrease in cash and cash equivalents	(8,174)	3,862
Net effect of exchange rate changes on cash and cash equivalents	(228)	700
Cash and cash equivalents, consolidated statement of cash flows, beginning balance	12,028	7,466
Cash and cash equivalents, consolidated statement of cash flows, ending balance	3,626	12,028
Cash and cash equivalents included in consolidated statement of cash flows consist of		
Balance as in statement of financial position (including cash restricted in use)	13,859	22,349
Less: Bank overdraft	(477)	(422)
Less: Restricted cash	(9,756)	(9,899)
Cash and cash equivalents for consolidated statement of cash flows purposes	3,626	12,028

(Registration Number: 200717793E)



1 (d) (i) Statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders together with a comparative statement for the corresponding period of the immediately preceding financial year.

GROUP	Share Capital US\$'000	Accumulated Losses US\$'000	Translation Reserve US\$'000	Other Reserve US\$'000	Reserve on Post- Employment Benefit US\$'000	Total US\$'000	Total Equity US\$'000
Balance as at 1/1/2020	93,860	(44,752)	(41,737)	2,485	-	9,856	9,856
Total comprehensive income/(loss)	-	4,021	42	-	(228)	3,835	3,835
Transferred to accumulated losses	-	(228)	-	-	228	-	-
Balance as at 31/12/2020	93,860	(40,959)	(41,695)	2,485	-	13,691	13,691
	-	-	-	-		-	-
Balance as at 1/1/2019	93,860	(32,042)	(42,159)	2,485	-	22,144	22,144
Total comprehensive (loss)/income	-	(12,821)	422	-	111	(12,288)	(12,288)
Transferred to accumulated losses		111	-	-	(111)	-	-
Balance as at 31/12/2019	93,860	(44,752)	(41,737)	2,485	-	9,856	9,856

COMPANY	Share Capital US\$'000	Retained Earnings US\$'000	Translation Reserve US\$'000	Total Equity US\$'000
Balance as at 1/1/2020	93,860	3,437	(25,588)	71,709
Total comprehensive loss	-	(808)	(1,038)	(1,846)
Balance as at 31/12/2020	93,860	2,629	(26,626)	69,863
Balance as at 1/1/2019	93,860	2,116	(28,439)	67,537
Total comprehensive income	-	1,321	2,851	4,172
Balance as at 31/12/2019	93,860	3,437	(25,588)	71,709

(Registration Number: 200717793E)



1 (d) (ii) Details of any changes in the Company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

There have been no changes in the Company's issued share capital since 31 December 2019. The Company has no outstanding share options, outstanding convertibles, treasury shares and subsidiary holdings as at 31 December 2020 and 31 December 2019.

The Company has not granted options or shares during the financial period ended 31 December 2020.

1 (d) (iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

Total number of issued shares (the Company has not held any treasury shares):

As at 31 December 2020	As at 31 December 2019
287,011,177	287,011,177

1 (d) (iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable.

1 (d) (v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable.

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The financial statements have not been audited or reviewed by the auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

(Registration Number: 200717793E)



3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer or opinion:- (a) Updates on the efforts taken to resolve each outstanding audit issue. (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed. This is not requited for any audit issues that is a material uncertainty relating to going convern.

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

The same accounting policies and methods of computation have been applied in these unaudited financial statements as those applied in the most recently audited financial statements as at 31 December 2019, except for the adoption of the new or revised Singapore Financial Reporting Standards (International) ("SFRS(I)") which became effective for the financial year beginning on or after 1 January 2020. The adoption of these new and revised SFRS(I) has no significant impact to the financial statements.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of the change.

Not applicable.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	2020	2019
	US Cents	US Cents
Earnings/(Loss) per share for the period		
(a) based on weighted average number of shares		
from continuing operations	1.40	(3.62)
from discontinued operations	0.00	(0.85)
Total earnings/(loss) per share attributable to ordinary equity holders of the Company	1.40	(4.47)
(b) based on a fully diluted basis		
from continuing operations	1.40	(3.62)
from discontinued operations	0.00	(0.85)
Total diluted earings/(loss) per share attributable to ordinary equity holders of the Company	1.40	(4.47)
Weighted number of shares	287,011,177	287,011,177

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the (a) current financial period reported on and (b) immediately preceding financial year.

	Gr	oup	Com	pany
	As at 31/12/2020	As at 31/12/2020 As at 31/12/2019		As at 31/12/2019
	US Cents	US Cents	US Cents	US Cents
Net asset value per ordinary share	4.77	3.43	24.34	24.98
Number of shares outstanding	287,011,177	287,011,177	287,011,177	287,011,177

(Registration Number: 200717793E)



8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Review of financial performance

Revenue and profit

The Group's revenue remained approximate that of 2019 despite reported a lower Crude Palm Oil ("CPO") sales volume. This was mainly due to higher Average Selling Price ("ASP") of CPO in 2020. ASP of CPO increased 19% from US\$450 in 2019 to US\$537 in 2020. Our CPO sales volume decreased by approximately 16% from 201,526 MT in 2019 to 169,060 MT in 2020. The decrease was mainly due to lower yield in Fresh Fruits Bunches (FFB) harvested in 2020.

For the year ended 31 December 2020, the Group recorded an operating profit ("OP") of US\$26.5 million and a net profit of US\$4.0 million. Our performance improved compared to that of 2019 and this was mainly attributable to higher ASP, lower cost of sales & other operation costs, lower interest expense and share of losses from equity accounted joint venture, offset by foreign exchange loss as a result of the IDR depreciating against the USD.

Cost of operation

Cost of sales decreased by 7% from US\$81.7 million in 2019 to US\$76.1 million in 2020. The decrease was mainly due to the drop in CPO sales volume and implementation of better cost control in CPO production.

Sales and distribution costs decreased by 30% from US\$2.6 million in 2019 to US\$1.8 million in 2020 mainly due to decrease in freight expenses.

Administrative expenses decreased slightly by 1.9% from US\$8.7 million in 2019 to US\$8.5 million in 2020. This was mainly due to lower travelling expenses incurred consequence to curtailing in travelling because of Covid-19 pandemic situation and lower bank charges spent.

Other losses comprise mainly of withholding and other tax expenses offset by plasma management fee income.

Interest income decreased by 74% from US\$3.3 million in 2019 to US\$0.9 million in 2020 mainly due to the capitalisation of interest-bearing loans to the equity of certain joint-venture entities.

Decrease in interest expenses was due to decrease in general interest rates.

Review of financial position

Shareholders' equity increased from US\$9.9 million as at 31 December 2019 to US\$13.7 million as at 31 December 2020 mainly due to profit for the period of US\$4.0 million.

The Group's total current assets decreased by US\$2.6 million from US\$93.4 million as at 31 December 2019 to US\$90.7 million as at 31 December 2020. Save for the movement in cash and cash equivalents as explained in the cash flow section below, the remaining movement in current assets arose mainly from:

(Registration Number: 200717793E)



- decrease in inventory amounting to US\$1.4 million mainly due to lower CPO stock on hand as at 31 December 2020;
- b) decrease in carrying value of asset held for sale was due to waiver of loan payables reclassification following the restructuring exercise as announced on 23 January 2020; and
- c) increase in biological assets amounting to US\$8.5 million due to higher estimated FFB production with better selling price.

Total non-current assets decreased by US\$21.4 million from US\$265.1 million as at 31 December 2019 to US\$243.7 million as at 31 December 2020. This was mainly due to the decrease in bearer plants and property, plant and equipment of US\$7.2 million and US\$9.2 million respectively as a result of depreciation.

The Group's total current liabilities decreased by US\$37.3 million from US\$147.8 million as at 31 December 2019 to US\$110.5 million as at 31 December 2020. This was mainly due to the following:

- a) decrease in trade and other payables amounting to US\$19.2 million mainly due to decrease in advances from customers; and
- b) decrease in other financial liabilities of US\$18.4 million due to decrease in current portion of long term borrowings as a result of refinancing activities and repayment of borrowings.

Total non-current liabilities increased by US\$9.4 million from US\$200.9 million as at 31 December 2019 to US\$210.3 million as at 31 December 2020 was mainly due to refinancing activities.

The Group reported negative working capital of US\$19.7 million as at 31 December 2020. This was mainly due to a portion of borrowings used to invest in plantation assets.

Review of group cash flows

The closing cash and cash equivalents (net of bank overdrafts and cash pledged) of the Group decreased by US\$8.4 million from US\$12.0 million as at 31 December 2019 to US\$3.6 million as at 31 December 2020. The decrease was due to net cash outflow from investing and financing activities offset by net cash inflow from operating activities.

The Group's operating cash flows was lower by US\$24.5 million in 2020 as compared to 2019 mainly due to decrease in advances from customers. The Group reported a net cash outflow used in investing activities of US\$1.4 million in 2020 mainly due to payment for property, plant and equipment and bearer plants. Net cash flows used in financing activities was US\$26.7 million mainly due to repayments of borrowings and interest offset by funding from new borrowings.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable.

(Registration Number: 200717793E)



10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

In the second half of 2020, CPO price surged to the highest level in 5-year period and this has reduced the pressure on the plantation business. As Covid-19 pandemic situation continues to impact the global economies, we remain cautiously optimistic on the sustainability of the current high CPO price. We will keep our focus on improving operational and financial efficiency and putting safety as a priority for all employees and stakeholders

11. Dividend

- (a) Current Financial Period Reported On
 Nil
- (b) Corresponding Period of the Immediately Preceding Financial Year
 Nil
- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated). Not applicable
- (d) Date payable

 Not applicable.
- (e) Books closure date Not applicable.

12. If no dividend has been declared/recommended, a statement to that effect and the reason for the decision

In view of the current market condition, no dividend has been declared or recommended for the financial period ended 31 December 2020.

(Registration Number: 200717793E)



13. If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the period under review (excluding transactions less than \$\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000)
		2020	2020
		<u>US\$'000</u>	<u>US\$'000</u>
Wilmar Group (1) (Sales)	Controlling shareholder	-	-
Wilmar Group (1) (Purchases)	Controlling shareholder	-	-
Wilmar Group (2) (Interest)	Controlling shareholder	183	-
PT Berkat Wahana Sukses ⁽³⁾ (Services Received, shareholders' mandate obtained at EGM held on 29 April 2019)	Associate of Maknawi family	1,963	-

⁽¹⁾ In respect of transactions conducted pursuant to General Mandate for transactions with Willmar Group.

14. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1).

The Company confirms that it has procured undertakings from all its directors and executive officers in the format set out in Appendix 7.7 under Rule 720(1) of the Listing Manual.

15. Segmented revenue and results for business or geographical segments (of the group) n the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediate preceding year.

The Group is primarily in the Oil Palm plantation business. The core business consists of cultivation of oil palm trees, processing of fresh fruit bunches into crude palm oil and palm kernel and the sale of crude palm oil and palm kernel. Accordingly, no segmental information is presented.

⁽²⁾ In respect of interest paid on trade payables due to Wilmar Group.

⁽³⁾ In respect of transactions conducted pursuant to Specific Mandate for transactions PT Berkat Wahana Sukses.

(Registration Number: 200717793E)



16. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.

Not applicable.

17. A breakdown of sales

· · · · · · · · · · · · · · · · · · ·					
		2020 US\$'000	2019 US\$'000	Increase/ (Decrease) US\$'000	
(a)	Sales reported for the first half year	61,684	45,676	16,008	
(b)	Operating profit before deducting non-controlling interests reported for the first half year	14,005	3,784	10,221	
(c)	Sales reported for the second half year	42,600	58,389	(15,789)	
(d)	Operating profit before deducting non-controlling interests reported for the second half year	12,447	12,164	283	

18. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:

No dividend has been declared or recommended for the financial years ended 31 December 2020 and 2019.

19. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(3). If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family Relationship with any Director, Chief Executive Officer and/or Substantial Shareholder	Current position and duties, and the year position was first held	Details of changes in duties held, if any, during the year
Albert Maknawi	40	Son of Henry Maknawi (Executive Chairman) Nephew of Ratna Maknawi (Executive Vice-Chairman)	Executive Director and Chief Executive Officer 2020 Responsible for the overall business strategies and the policies of the Group. Mr Maknawi continues to oversee the Group's overall operating activities, including strategic planning of the Group. Chief Executive Officer 2018 Responsible for the overall business strategic and policies of the Group.	Executive Director and Chief Executive Officer

(Registration Number: 200717793E)



			Chief Operating Officer	
			2011	
			Overseeing the Group's overall operational	
			activities, including strategic planning for the	
			Group.	
			Group.	
			Deputy Chief Operating Officer	
			<u>2010</u>	
			Assisting the Chief Operating Officer on the	
			day-to-day operations, including strategic	
			planning for the Group.	
			Planta of Challes to	
			Director of Subsidiaries:	
			<u>2017</u>	
			PT Sawit Permai Lestari	
			PT Wira Palm Mandiri	
			PT Mentari Bangun Persada	
			PT Citra Megah Kencana	
			2015	
			Global Eastern Capital Pte. Ltd.	
			'	
			<u>2010</u>	
			PT Bumi Permai Sentosa	
			2007	
			2007	
			Sawindo Agri Pte. Ltd.	
			Director of subsidiary of Joint Venture	
			Company:	
			2010	
			PT Cahaya Permata Gemilang	
			<u>2007</u>	
			PT Listrindo Kencana	
			PT Belintung Energy	
			Commissioner of subsidiaries of Joint	
			Venture Company:	
			2014	
			PT Energy Cipta Usaha	
			PT Energy Karya Persada	
Ajis	57	Brother-in-law of Henry	Director of Subsidiaries:	No change
Chandra	-	Maknawi (Executive	2010	2 2 2 3 3 6 2
		Chairman)	PT Bumi Permai Sentosa	
		Husband of Ratna		
		Maknawi (Executive	2007	
		Vice-Chairman)	Kencana Logistics Pte. Ltd.	
		The chairman,		

(Registration Number: 200717793E)



Augyawati Joe	41	Niece of: - Henry Maknawi (Executive Chairman) - Ratna Maknawi (Executive Vice-Chairman)	Director of Subsidiaries: 2015 Global Eastern Capital Pte. Ltd. 2008 Sawindo Agri Pte. Ltd. Kencana Logistics Pte. Ltd. Kencana Plantations Pte. Ltd.	No change
Eddy Maknawi	58	Brother of Henry Maknawi (Executive Chairman) Brother of Ratna Maknawi (Executive Vice-Chairman)		No change

(Registration Number: 200717793E)



20. Additional Information Required Pursuant to Rule 706A

Save as the announcements made on 31 October 2019, 23 January 2020 and 5 May 2020 in relation to the disposal and internal restructuring of Kencana Bio-Energy Pte Ltd and its subsidiaries (asset held for sale) to an interested party, Kencana Energy Lestari Tbk, the Company did not acquire or dispose any shares which would result in any company becoming or ceasing to be a subsidiary or associated company of the Company, or increase or reduce the Company's shareholding percentage in any subsidiary or associated company.

As at the date of this announcement, the transaction pertaining to the disposal of asset held for sale has yet to be completed.

BY ORDER OF THE BOARD Henry Maknawi Executive Chairman 1 March 2021